- Home
- MGNI vs NVAX Comparison
MGNI vs NVAX Comparison
Compare MGNI & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- NVAX
- Stock Information
- Founded
- MGNI 2007
- NVAX 1987
- Country
- MGNI United States
- NVAX United States
- Employees
- MGNI N/A
- NVAX N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGNI Technology
- NVAX Health Care
- Exchange
- MGNI Nasdaq
- NVAX Nasdaq
- Market Cap
- MGNI 3.1B
- NVAX 1.4B
- IPO Year
- MGNI N/A
- NVAX 1995
- Fundamental
- Price
- MGNI $17.10
- NVAX $7.69
- Analyst Decision
- MGNI Strong Buy
- NVAX Hold
- Analyst Count
- MGNI 11
- NVAX 7
- Target Price
- MGNI $26.18
- NVAX $10.71
- AVG Volume (30 Days)
- MGNI 2.7M
- NVAX 4.2M
- Earning Date
- MGNI 11-05-2025
- NVAX 11-06-2025
- Dividend Yield
- MGNI N/A
- NVAX N/A
- EPS Growth
- MGNI 211.62
- NVAX N/A
- EPS
- MGNI 0.38
- NVAX 2.54
- Revenue
- MGNI $702,565,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- MGNI $2.09
- NVAX $59.49
- Revenue Next Year
- MGNI $11.41
- NVAX N/A
- P/E Ratio
- MGNI $45.00
- NVAX $3.02
- Revenue Growth
- MGNI 6.27
- NVAX 9.22
- 52 Week Low
- MGNI $8.22
- NVAX $5.01
- 52 Week High
- MGNI $26.65
- NVAX $11.55
- Technical
- Relative Strength Index (RSI)
- MGNI 36.04
- NVAX 38.85
- Support Level
- MGNI $17.28
- NVAX $7.50
- Resistance Level
- MGNI $18.41
- NVAX $8.66
- Average True Range (ATR)
- MGNI 0.87
- NVAX 0.34
- MACD
- MGNI -0.06
- NVAX -0.12
- Stochastic Oscillator
- MGNI 17.30
- NVAX 14.34
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.